Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Download PDF Copy

Dec 15 2009

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.

The submission is based on a comprehensive clinical development program for JZP-6, including results from two Phase III clinical trials. In both trials, sodium oxybate significantly decreased pain and fatigue as well as improved daily function, patient global impression of change, and sleep quality. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.

Fibromyalgia is a complex musculoskeletal disorder clinically characterized by widespread pain usually accompanied by fatigue, insomnia, and dyscognition. According to the American College of Rheumatology (ACR), an estimated 6 million Americans suffer from fibromyalgia.

Source: http://www.jazzpharma.com/

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Innovative approaches target PAR2 receptor to alleviate gut pain

University of Maine team develops sustainable method to cut drug production costs

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

Global cancer cases and deaths expected to soar by 2050 despite advances in treatment

‘Sick to my stomach’: Trump distorts facts on autism, tylenol, and vaccines, scientists say

Study sheds light on how inadequate sleep in teens can contribute to cycles of violence

Off-label drug helps one boy with autism speak, parents say. But experts want more data.

Scientists test whether chaya leaves can lower blood sugar in diabetes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.